Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Sandén, Carl ^a   Ageberg, Malin ^a   Petersson, Jessica ^a   Lennartsson, Andreas ^b   Gullberg, Urban ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute myeloid leukemia; DEK CAN; DEK NUP214; Everolimus; Fusion gene; mTOR; Proliferation

Indexed keywords

DEK NUP214 PROTEIN; EVEROLIMUS; GLUCOSE; HYBRID PROTEIN; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P70; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; DOWNSTREAM PROCESSING; GENE EXPRESSION; GLUCOSE METABOLISM; GLYCOLYSIS; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; UPREGULATION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION; GLYCOLYSIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDATIVE PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; U937 CELLS;

EID: 84884733616     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-440     Document Type: Article

References (36)

1. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006, 107(9):2099-2107. 10.1002/cncr.22233, 17019734.
2. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006, 20(7):1295-1297. 10.1038/sj.leu.2404233, 16628187.
3. von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A, Grosveld G. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992, 12(4):1687-1697. 369612, 1549122.
4. Ageberg M, Drott K, Olofsson T, Gullberg U, Lindmark A. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis. Genes Chromosomes Cancer 2008, 47(4):276-287. 10.1002/gcc.20531, 18181180.
5. Oancea C, Ruster B, Henschler R, Puccetti E, Ruthardt M. The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. Leukemia 2010, 24(11):1910-1919. 10.1038/leu.2010.180, 20827285.
6. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99(12):4326-4335. 10.1182/blood.V99.12.4326, 12036858.
7. Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood 2004, 103(5):1883-1890. 10.1182/blood-2003-06-1978, 14592841.
8. Boer J, Bonten-Surtel J, Grosveld G. Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis. Mol Cell Biol 1998, 18(3):1236-1247. 108836, 9488438.
9. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010, 1804(3):433-439. 10.1016/j.bbapap.2009.12.001, 20005306.
10. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle 2011, 10(14):2305-2316. 10.4161/cc.10.14.16586, 3322468, 21670596.
11. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18(16):1926-1945. 10.1101/gad.1212704, 15314020.
12. Sonenberg N, Gingras AC. The mRNA 5' cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998, 10(2):268-275. 10.1016/S0955-0674(98)80150-6, 9561852.
13. Waskiewicz AJ, Johnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 1999, 19(3):1871-1880. 83980, 10022874.
14. Ramanathan A, Schreiber SL. Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci U S A 2009, 106(52):22229-22232. 10.1073/pnas.0912074106, 2796909, 20080789.
15. Schieke SM, Phillips D, McCoy JP, Aponte AM, Shen RF, Balaban RS, Finkel T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 2006, 281(37):27643-27652. 10.1074/jbc.M603536200, 16847060.
16. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007, 13(10):433-442. 10.1016/j.molmed.2007.08.001, 17905659.
17. Coppin C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics 2010, 4:91-101. 2880340, 20531964.
18. Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 2009, 23(2):77-91. 10.2165/00063030-200923020-00002, 19489650.
19. O'Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 2010, 3(2):65-79. 2847314, 20360931.
20. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3(6):1101-1108. 10.1038/nprot.2008.73, 18546601.
21. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl 2):S43-S51. 3752670, 19956179.
22. Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010, 115(11):2127-2135. 10.1182/blood-2009-09-220020, 2844014, 20075156.
23. Saito S, Nouno K, Shimizu R, Yamamoto M, Nagata K. Impairment of erythroid and megakaryocytic differentiation by a leukemia-associated and t(9;9)-derived fusion gene product, SET/TAF-Ibeta-CAN/Nup214. J Cell Physiol 2008, 214(2):322-333. 10.1002/jcp.21199, 17620317.
24. Chung KY, Morrone G, Schuringa JJ, Plasilova M, Shieh JH, Zhang Y, Zhou P, Moore MA. Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res 2006, 66(24):11781-11791. 10.1158/0008-5472.CAN-06-0706, 17178874.
25. Jankovic D, Gorello P, Liu T, Ehret S, La Starza R, Desjobert C, Baty F, Brutsche M, Jayaraman PS, Santoro A, et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia (AML). Blood 2008, 111(12):5672-5682. 10.1182/blood-2007-09-108175, 18388181.
26. Takeda A, Goolsby C, Yaseen NR. NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. Cancer Res 2006, 66(13):6628-6637. 10.1158/0008-5472.CAN-06-0458, 16818636.
27. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004, 125(5):590-600. 10.1111/j.1365-2141.2004.04952.x, 15147374.
28. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A 2008, 105(36):13544-13549. 10.1073/pnas.0800041105, 2533226, 18768809.
29. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110(2):163-175. 10.1016/S0092-8674(02)00808-5, 12150925.
30. Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R, Sterneck E. The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J 2010, 29(24):4106-4117. 10.1038/emboj.2010.280, 3018791, 21076392.
31. Kaizuka T, Hara T, Oshiro N, Kikkawa U, Yonezawa K, Takehana K, Iemura S, Natsume T, Mizushima N. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J Biol Chem 2010, 285(26):20109-20116. 10.1074/jbc.M110.121699, 2888423, 20427287.
32. Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 2005, 280(28):26089-26093. 10.1074/jbc.M504045200, 15905173.
33. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005, 280(27):25485-25490. 10.1074/jbc.M501707200, 15899889.
34. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010, 10(4):254-266. 10.1038/nrc2824, 20332778.
35. Ferreira LM. Cancer metabolism: the Warburg effect today. Exp Mol Pathol 2010, 89(3):372-380. 10.1016/j.yexmp.2010.08.006, 20804748.
36. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, Jezek P. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 2011, 43(7):950-968. 10.1016/j.biocel.2010.05.003, 20460169.